Search clinical trials for: GRC 54276 Pembrolizumab

Total 3417 results

Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR)

Withdrawn

Effect of Probiotic Lactobacilli on Vaginal Flora of Pregnant Women at High Risk for Preterm Delivery

Premature Birth | Bacterial Vaginosis

Canada
Genentech, Inc.

Completed

An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)

Healthy Volunteers
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Active, not recruiting

Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer

Metastatic Lung Cancer | Stage IV Lung Cancer

United States
Camlin Ltd
Università Politecnica delle Marche

Completed

At Home REhabilitation and Monitoring of People in poST-covid Condition Through ARc-inTellicare Platform (RESTART/RICOMINCIARE) (RICOMINCIARE)

Parkinson Disease | Post-COVID19

Italy
Genentech, Inc.

Completed

A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Solid Cancers
Genentech, Inc.

Completed

A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Solid Cancers

United States, United Kingdom
Genentech, Inc.

Completed

A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Non-Hodgkin's Lymphoma, Solid Cancers

United Kingdom
Genentech, Inc.

Completed

Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Solid Tumor

Canada, United States
Genentech, Inc.

Completed

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors

Solid Cancers

United States
Genentech, Inc.

Completed

A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy Volunteers

Healthy Volunteer

United States
Genentech, Inc.

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects

Healthy Volunteer

United States
Seoul National University Bundang Hospital

Unknown

Incidence of Venous Thromboembolism Following Surgery in Patients With Colorectal Cancer

Symptomatic Venous Thromboembolism | Asymptomatic Venous Thromboembolism

Korea, Republic of
Shanghai Minimally Invasive Surgery Center

Recruiting

Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen

Gastric Cancer Stage IIIB-IIIC

China
Yonsei University

Not yet recruiting

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Soft Tissue Sarcoma
Stanford University
Merck Sharp & Dohme LLC

Recruiting

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Thyroid Cancer

United States
Henry Ford Health System

Recruiting

HFHS-1801-A Pilot Study of Immunotherapy as Consolidation Therapy for Patients With Recurrent Head and Neck Cancer

Head and Neck Neoplasms

United States
Sanford Health
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Combination With CRT for LA-SCCHN

Head and Neck Cancer | Laryngeal Cancer | Oropharynx Cancer | Oral Cavity Cancer | Larynx Cancer | Squamous Cell Carcinoma | Hypopharynx Cancer

United States
CG Oncology, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (CORE-001)

Non Muscle Invasive Bladder Cancer

United States, Korea, Republic of
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

rrCLL | rrMM | rrDLBCL
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm
Xencor, Inc.
ICON Clinical Research

Completed

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)

Melanoma | Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Fallopian Tube Cancer | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Intrahepatic Cholangiocarcinoma and other conditions

United States
Merck Sharp & Dohme LLC

Terminated

Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)

Advanced Solid Tumor
Haider Mahdi
Mirati Therapeutics Inc.

Withdrawn

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Solid Tumors | Recurrent Endometrial Cancer

United States
Seagen Inc.

Terminated

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

Carcinoma, Renal Cell | Breast Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Carcinoma, Squamous Cell of Head and Neck | Urinary Bladder Neoplasm

United States
National Cancer Institute (NCI)
Genentech, Inc.

Terminated

Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

Chronic Graft Versus Host Disease

United States
Genentech, Inc.

Terminated

Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

United States
Iovance Biotherapeutics, Inc.

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Melanoma | Metastatic Melanoma | Unresectable Melanoma

United States, Spain, Australia, France, Netherlands, Italy, Canada, Sweden
University of Kansas Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Adenocarcinoma | Stomach Cancer | Gastro Esophageal Junction Cancer

United States
Genentech, Inc.

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential

Healthy Volunteers

United Kingdom
Shyam S.D. Rao
National Cancer Institute (NCI)

Recruiting

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

Metastatic Head and Neck Squamous Cell Carcinoma | Locally Recurrent Head and Neck Squamous Cell Carcinoma | Refractory Head and Neck Squamous Cell Carcinoma

United States
Gritstone bio, Inc.

Completed

Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV)

COVID-19 | SARS-CoV-2

South Africa
China Medical University Hospital

Completed

Probiotic on Prevention of GBS Vaginal Infection During Pregnancy (GBS)

Infection, Bacterial

Taiwan
Baylor College of Medicine
Lawson Health Research Institute; Chr Hansen

Unknown

Bacteriuria Eradication Through Probiotics (BERP)

Bacteriuria

United States
Vasgene Therapeutics, Inc

Recruiting

A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma

Metastatic Urothelial Carcinoma

United States
Diwakar Davar
Merck Sharp & Dohme LLC

Active, not recruiting

Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)

Squamous Cell Carcinoma

United States
Yonsei University

Completed

Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)

Esophageal Squamous Cell Carcinoma

Korea, Republic of
National Cancer Institute (NCI)

Completed

Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma

Adult Medulloblastoma

United States
Ikena Oncology
Gilead Sciences

Terminated

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Gynecologic Cancer | Colorectal Cancer | Pancreatic Cancer | Gastric Adenocarcinoma | Lung Adenocarcinoma | Advanced Solid Tumor

United States
Chloe Atreya, MD, PhD
Merck Sharp & Dohme LLC; MedPacto, Inc.

Recruiting

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

Metastatic Malignant Neoplasm in the Liver | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8

United States
Prof. Dr. med. Christian Gratzke
Merck Sharp & Dohme LLC

Recruiting

SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy (Pembro-SRT)

Urologic Cancer | Biochemical Recurrence of Malignant Neoplasm of Prostate

Germany
Tianjin Medical University Cancer Institute and...

Recruiting

Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma (KEYSTONE-003)

Pembrolizumab | Neoadjuvant Chemotherapy | Adenocarcinoma of Esophagogastric Junction

China
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)

Solid Tumor, Adult

United States, Sweden
Merck Sharp & Dohme LLC

Terminated

A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

Neoplasm Metastasis

United States, Canada, Israel
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Institute of Cancer Research, United Kingdom

Terminated

PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck (PEACH)

Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma

United Kingdom
The Netherlands Cancer Institute
Merck Sharp & Dohme LLC

Completed

Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC (PEMBRO-RT)

Non-Small Cell Lung Cancer

Netherlands
Yonsei University
Genexine, Inc.; NeoImmuneTech

Recruiting

Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer (GENUINE)

Head and Neck Squamous Cell Carcinoma

Korea, Republic of
Memorial Sloan Kettering Cancer Center
CANCER PREVENTION FUND

Recruiting

A Study of Using Social Networks to Encourage Three Peers to Complete Screening for Colorectal Cancer

Colon Cancer Screening

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Study of Vaccination Schedule of Experimental HIV Vaccines

HIV Infections

United States
Rhodes Pharmaceuticals, L.P.
Purdue Pharma LP

Completed

PRC-063 in an ADULT Workplace Environment

Attention Deficit Hyperactivity Disorder (ADHD)

United States

Search clinical trials for: GRC 54276 Pembrolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations